Cytokinetics develops heart-muscle drugs, led by aficamten.
Cytokinetics, Incorporated (CYTK) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 16:05 ET. Consensus EPS estimate is $-1.45.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | FY2026 Q2 | $-1.63 | $-1.50 | +8.0% | $31.91M |
| 2026-05-05 | FY2026 Q1 | $-1.67 | $-1.67 | +0.0% | $19.36M |
| 2026-02-26 | FY2025 Q4 | $-1.48 | $-1.49 | -0.7% | $17.75M |
| 2025-11-05 | FY2025 Q3 | $-1.59 | $-2.55 | -60.4% | $1.94M |
| 2025-08-07 | FY2025 Q2 | $-1.34 | $-1.12 | +16.4% | — |
| 2025-05-06 | FY2025 Q1 | $-1.41 | $-1.36 | +3.5% | $1.58M |
| 2025-02-27 | FY2024 Q4 | $-1.29 | $-1.27 | +1.6% | $16.93M |
| 2024-05-10 | FY2024 Q1 | $-1.16 | $-1.33 | -14.7% | $835.00K |
CYTK has beaten consensus EPS in 5 of its last 8 reported quarters.
Highlights from CYTK's Aug 6 report: EPS of -$1.50 — a beat vs the -$1.63 estimate (+8%); revenue of $32M — a big beat vs the $18M consensus (+81%). Focus now shifts to aficamten launch preparation.
See CYTK on the live calendar →